Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.50 |
| ▸ | DDAH1 | O94760 | 2/20 | 0.43 |
| ▸ | GSR | P00390 | 2/20 | 0.43 |
| ▸ | NOS2 | P35228 | 3/20 | 0.41 |
| ▸ | NOS3 | P29474 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.41 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25216092 | 1.00 | OTC (0.50) | OTCDDAH1GSRNOS2NOS3 | |
| SCHEMBL9974075 | 0.87 | OTC (0.48) | OTCDDAH1GSRNOS2NOS3 | |
| SCHEMBL13059111 | 0.85 | OTC (0.51) | OTCDDAH1GSRNOS2NOS3 | |
| SCHEMBL1004634 | 0.83 | OTC (0.50) | OTCDDAH1GSRNOS2NOS3 | |
| SCHEMBL21089975 | 0.83 | OTC (0.50) | OTCDDAH1GSRNOS2NOS3 | |
| SCHEMBL3508097 | 0.83 | OTC (0.50) | OTCDDAH1GSRNOS2NOS3 | |
| SCHEMBL24451312 | 0.83 | OTC (0.50) | OTCDDAH1GSRNOS2NOS3 | |
| SCHEMBL8730134 | 0.83 | NOD1 (0.52) | OTCDDAH1GSRNOS2NOS3 | |
| SCHEMBL12028765 | 0.83 | OTC (0.50) | OTCDDAH1GSRNOS2NOS3 | |
| SCHEMBL18532015 | 0.83 | OTC (0.53) | OTCDDAH1GSRNOS2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12044684-B2 | Methods for diagnosing an autistic spectrum disorder | QATAR UNIVERSITY (QA) | 2024-07-23 | — | — | US | claimed |
| US-20210033621-A1 | METHODS FOR DIAGNOSING AN AUTISTIC SPECTRUM DISORDER | QATAR UNIVERSITY (QA) | 2021-02-04 | — | — | US | claimed |
| CN-119064480-A | Screening method of UPLC-MS-based drug for inhibiting activity of advanced glycosylation end product | 南京理工大学 | 2024-12-03 | — | — | CN | disclosed |
| US-12044684-B2 | Methods for diagnosing an autistic spectrum disorder | QATAR UNIVERSITY (QA) | 2024-07-23 | — | — | US | disclosed |
| CN-117677839-A | Method and device for detecting biological molecules | 国立大学法人东京大学 | 2024-03-08 | — | — | CN | disclosed |
| WO-2023002892-A1 | METHOD AND DEVICE FOR DETECTING BIOMOLECULE | 国立大学法人 東京大学 | 2023-01-26 | — | — | WO | disclosed |
| US-20210033621-A1 | METHODS FOR DIAGNOSING AN AUTISTIC SPECTRUM DISORDER | QATAR UNIVERSITY (QA) | 2021-02-04 | — | — | US | disclosed |
| WO-2017149300-A1 | MARKERS FOR SKELETAL DISORDERS | THE UNIVERSITY OF WARWICK (GB) | 2017-09-08 | — | — | WO | disclosed |
| US-9040553-B2 | Phenoxyisobutyric acid compounds and method of synthesis | Cell Viable Corporation (US) | 2015-05-26 | — | — | US | disclosed |
| US-20140371316-A1 | DERIVATIVES OF PHENOXYISOBUTYRIC ACID | FABRICANT JILL S (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140350045-A1 | PHENOXYISOBUTYRIC ACID COMPOUNDS AND METHOD OF SYNTHESIS | LALEZARI IRAJ (US) | 2014-11-27 | — | — | US | disclosed |
| US-6787566-B2 | ADMINISTERING AN EFFECTIVE AMOUNT OF A COMPOUND SELECTED FROM ARYL(AND HETEROCYCLIC) UREIDO AND ARYL(HETEROCYCLIC) CARBOXAMIDO PHENOXYISOBUTYRIC ACIDS AS INHIBITOR OF GLYCATION AND ADVANCED GLYCATION ENDPRODUCTS (AGES) (PROTEIN-AGING) | CITY OF HOPE | 2004-09-07 | — | — | US | disclosed |
| WO-2004071416-A2 | NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGES) | CITY OF HOPE (US) | 2004-08-26 | — | — | WO | disclosed |
| EP-1372627-A1 | USE OF BREAKERS OF ADVANCED GLYCATION ENDPRODUCTS FOR TREATING DELETERIOUS EFFECTS OF AGING AND DEBILITATING DISEASES | CITY OF HOPE (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030220362-A1 | Novel inhibitors of formation of advanced glycation endproducts (AGEs) | CITY OF HOPE | 2003-11-27 | — | — | US | disclosed |
| US-6605642-B2 | Administering specified compounds which are derivatives of phenoxyisobutyric acids and of benzoic acid including aryl and heterocyclic ureido derivatives and aryl and heterocyclic carboxamido derivatives; treating aging, arthritis, diabetes | CITY OF HOPE | 2003-08-12 | — | — | US | disclosed |
| US-6589944-B1 | A method of cleaving glycation endproducts or cross-linked proteins in an organism in need thereof, wherein said method comprises administering an effective amount of a compound or pharmaceutically acceptable salt thereof to said organism for | CITY OF HOPE | 2003-07-08 | — | — | US | disclosed |
| WO-2002076443-A1 | USE OF BREAKERS OF ADVANCED GLYCATION ENDPRODUCTS FOR TREATING DELETERIOUS EFFECTS OF AGING AND DEBILITATING DISEASES | CITY OF HOPE (US) | 2002-10-03 | — | — | WO | disclosed |
| US-20020013256-A1 | Novel inhibitors of formation of advanced glycation endproducts (AGES) | PROSCIENCE CORPORATION, INCORPORATED IN THE STATE OF NEW YORK | 2002-01-31 | — | — | US | disclosed |
| US-20020002203-A1 | Novel breakers of advanced glycation endproducts | CITY OF HOPE | 2002-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002203-A1 | Novel breakers of advanced glycation endproducts | AGER, SSB, MRPS18B | OTC 1327/4885DDAH1 1771/4885GSR 452/4885 |
| US-20140350045-A1 | PHENOXYISOBUTYRIC ACID COMPOUNDS AND METHOD OF SYNTHESIS | AGER, BPGM, PDXK | OTC 417/4885DDAH1 2652/4885GSR 1897/4885 |
| US-20140371316-A1 | DERIVATIVES OF PHENOXYISOBUTYRIC ACID | AGER, BPGM, FOSB | OTC 331/4885DDAH1 3650/4885GSR 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.